|
|
Medical Education
Library:
Managing Cutaneous T-Cell Lymphoma and
Related Diseases: An Update for Clinicians
A supplement to Skin & Allergy News, supported
by an educational grant from Ligand Pharmaceuticals. The
articles in this supplement are based on faculty
presentations given at a satellite symposium during Skin
Disease Education Foundation’s 30th Annual Hawaii
Dermatology Seminar, a continuing medical education program
held February 11-18, 2006, in Kauai, Hawaii.
Topics:
- Target Audience
- Educational Needs
- Learning Objectives
- CME
Recognition
|
Topic:
Topical Treatment of Cutaneous T-Cell-Mediated Diseases:
Targeting T Cells
Faculty
Marie-France Demierre, MD, FRCPC
Associate Professor of
Dermatology and Medicine
Boston
University School of Medicine
Director, Skin Oncology Program
Boston Medical Center Boston,
Mass.
Topic: Innovative Strategies for
Managing Patients With Cutaneous
Lymphomas
John A. Zic, MD
Assistant Professor of
Medicine/Dermatology
Director,
Vanderbilt University Cutaneous Lymphoma Clinic
Division of Dermatology
Vanderbilt University Medical Center
Nashville, Tenn. |
Back to top  |
Faculty
Disclosures
The faculty of this CME activity
disclose the following:
| Faculty Member |
|
|
|
Marie-France Demierre,
MD, FRCPC |
Dr. Demierre has received funding
from Ligand Pharmaceuticals Inc. for Mycosis Fungoides
Foundation Surveys. She is also a consultant to and has
a Speaker Agreement with Ligand. She discusses the
investigational use of bexarotene gel 1% in the
treatment of hand dermatitis, psoriasis, and alopecia
areata. |
|
John A. Zic, MD
|
Dr. Zic has received funding for a
photopheresis study from Therakos, Inc., and is on the
Speakers’ Boards at Ligand and Therakos. He is also a
consultant to Ligand. Dr. Zic discusses the
investigational combined use of gemcitabine and
pegylated liposomal doxorubicin for the treatment of
advanced cutaneous T-cell lymphoma. |
| |
| Back to top |
Target Audience
This supplement was developed for dermatologists and
other clinicians who are involved in the diagnosis and
treatment of patients with the cutaneous manifestations of
cutaneous T-cell lymphoma and natural killer cell lymphoma.
|
Educational
Needs
Cutaneous T-cell lymphoma (CTCL) is a group of related
autoimmune diseases that share an underlying
pathology—namely, a malignancy of T cells—and that usually
present initially with skin lesions. However, the cause is
unknown. The typical clinical course of CTCL is chronic and
is characterized by slow progression; the number of years of
survival depends on the stage of the disease at the time of
diagnosis. Patients who present with the earliest stage of
the disease—ie, stage I skin involvement—may expect
long-term survival if CTCL is treated early, and topical
therapy often is effective when begun at this
stage.
For these reasons,
dermatologists must be familiar with the diagnosis of CTCL
and with effective treatment options for patients at all
stages of the disease. These options include oral therapy
with bexarotene capsules and a novel topical therapy,
bexarotene gel 1%, which has been approved by the US Food
and Drug Administration for the treatment of cutaneous
manifestations of CTCL. Bexarotene also is being studied in
other cutaneous diseases that share with CTCL the underlying
feature of abnormal T-cell activation and pathologic
increase in cytokine production. This supplement provides
dermatologists with updates on both research and practical
clinical management. |
| Back to top |
Learning Objectives
By reading and studying this
supplement, participants should be able to:
· Discuss the
classification and staging of cutaneous T-cell lymphoma and
natural killer cell lymphoma, and state the prognosis
associated with each stage.
· List and
describe the skin-directed and systemic treatment options
that are appropriate for each stage and cutaneous
manifestation of cutaneous T-cell
lymphoma.
· Discuss the
algorithm for treatment of mycosis fungoides and Sézary
syndrome described by John A. Zic,
MD.
· Describe the clinical
studies of bexarotene and explain the role of bexarotene
topical gel and oral formulation (capsules) in the treatment
of cutaneous T-cell
lymphoma.
|
| Back to top |
CME
Recognition
This Skin & Allergy News
supplement is recognized by the American Academy
of Dermatology (AAD) for 1 hour of AAD Category 1 CME credit
and may be used toward the American Academy of Dermatology’s
Continuing Medical Education Award.
This program was developed in
accordance with the Accreditation Council for Continuing
Medical Education guidelines.
Term of
Approval: July 2006—June 30, 2007
Estimated time to complete
this educational activity: 1 hour.
Copyright © 2006 Elsevier Inc.
|